Clinical Advances in

The HER2 Landscape: Past, Present, and Future

Supported by an independent educational grant from AstraZeneca

Astra Zeneca

CME Activities

Addressing the Challenge of Endocrine-Resistant Breast Cancer

Medscape Education, May 2022

Did you know that estrogen receptor-positive breast cancer often develops treatment resistance to endocrine therapy?

0.50 CME
HER2 Testing for the Pathologist: Is Your Clinic Up to Date With the Latest Developments?

Medscape Education, February 2021

Join the faculty for a discussion on the latest guidelines and challenges in HER2 testing in solid tumors.
The Changing Landscape for HER2+ Advanced Breast Cancer: Clinical Experience With Anti-HER2 Agents

Medscape Education, January 2021

Expert faculty discuss new agents for the treatment of HER2-positive advanced breast cancer.

0.50 CME
The Why, When, and How of HER2 Testing: Expert Recommendations for the Clinics

Medscape Education, November 2020

Giuseppe Viale provides a summary of the data presented at a recent live symposium on HER2 testing.
Expanding Options for Patients With HER2-Positive Advanced Breast Cancer: What Differentiates Novel Therapies?

Medscape Education, November 2020

Dr. Harbeck summarizes the key highlights from the live event on HER2-positive advanced breast cancer.

0.25 CME
Novel HER2-Directed Therapies: Updates and Clinical Implications

Medscape Education, July 2020

This educational activity is intended for an international audience of non-US hem/onc specialists.

The HER2 Landscape

What Can HER2 Testing Tell Us About Solid Tumors?

Resources

Downloadable Slide Kit

Clinical Advances in the HER2 Landscape: Past, Present, and Future

Clinical Reference

Steering Committee

Fatima Cardoso, MD

Steering Committee Member Chair

Breast Unit
Champalimaud Clinical Centre
Lisbon, Portugal

Giuseppe Curigliano, MD

University of Milano
European Institute of Oncology
Milan, Italy

Ian Krop, MD

Breast Cancer Division, Dana Farber Cancer Institute, Boston, MA

Enriqueta Felip, MD

Vall d'Hebron University Hospital, Barcelona, Spain

Jeeyun Lee, MD

Samsung Medical Center
South Korea

Giuseppe Viale, MD

University of Milan, Italy

Steering Committee

Fatima Cardoso

Chair

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo. Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Samsung Bioepis, Sanofi, Seattle Genetics, Teva

Giuseppe Curigliano, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca; BMS; Daichii Sankyo; Lilly; Merck; Novartis; Pfizer; Roche; Veracyte

Served as a speaker or a member of a speakers bureau for: Roche; Veracyte

Received grants for clinical research from: Merck

Ian Krop, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca; Celltrion; Daiichi Sankyo; Genentech/Roche; Macrogenics

Received grants for clinical research from: Genentech/Roche; Pfizer

Other: Merck (DSMB member); Novartis (DSMB Member)

Eneiqueta Felip, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbvie; AstraZeneca; Bayer; Blue Print Medicines; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli Lilly; GSK; Guarant Health; Janssen; Merck; MSD; Novartis; Pfizer; Roche; Takeda

Served as a speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eli Lilly; Medscape; MSD; Novartis; Pfizere; Prime Oncology; Roche; Takeda; TopChem

Received grants for clinical research from: Merck; Oncology Innovation (GOI) Fundacion; Salud

Other: Independent Member of the Board Grifols

Jeeyun Lee

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Mirati; Oncologie; Seattle Genetics

Received grants for clinical research from: AstraZeneca; Merck; MSD

Giuseppe Viale, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca; Bayer; Daichii Sankyo; Dako-Agilent; Eli-Lilly; Menarini; MSD Oncology; Novartis; Roche/Genentech

Served as a speaker or a member of a speakers bureau for: Bayer; Roche/Genentech

Received grants for clinical research from: Cepheid; Dako-Agilent; Ventana